Drugs Made In America Acquisition II Corp Right
DMIIR
47 hedge funds and large institutions have $4.53M invested in Drugs Made In America Acquisition II Corp Right in 2025 Q4 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$386K |
| 2 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$295K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$281K |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$271K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$233K |
Top Sellers
DMIIR Hedge Fund Activity: Q4 2025 in Review
47 of the 8,282 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Right (DMIIR) for Q4 2025, worth a combined $4.53M.
Buyers outnumbered sellers: 47 funds opened new DMIIR positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $386K.
- 47 institutional investors held Drugs Made In America Acquisition II Corp Right (DMIIR) as of Q4 2025, up from 0 in Q3 2025.
- Funds reported $4.53M of Drugs Made In America Acquisition II Corp Right stock for Q4 2025.
- 47 funds opened new Drugs Made In America Acquisition II Corp Right positions in Q4 2025 and 0 closed out, a net change of +47 holders.
- The largest Drugs Made In America Acquisition II Corp Right buyer in Q4 2025 was Magnetar Financial, an estimated $386K added.
Based on aggregated 13F filings for Q4 2025.